Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933303 | 0.96 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL29203338 | 0.96 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL24933482 | 0.93 | FFAR1 (0.32) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL30240755 | 0.89 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL30240729 | 0.89 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL30240775 | 0.89 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL24933300 | 0.89 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL24933295 | 0.89 | HSD17B1 (0.33) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL30240724 | 0.88 | HSD17B1 (0.34) | HSD17B1HSD17B2FFAR1PARP1 | |
| SCHEMBL30240741 | 0.88 | HSD17B1 (0.34) | HSD17B1HSD17B2FFAR1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |